The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 and older.
Arexvy, manufactured by GlaxoSmithKline (GSK), is expected to help prevent lower respiratory tract infections caused by RSV, the agency said Wednesday.
“Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV,” Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in an FDA news release.
